# Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers

> **NCT00215826** · PHASE2 · COMPLETED · sponsor: **AIM ImmunoTech Inc.** · enrollment: 10 (actual)

## Conditions studied

- Severe Acute Respiratory Syndrome

## Interventions

- **DRUG:** Alferon LDO

## Key facts

- **NCT ID:** NCT00215826
- **Lead sponsor:** AIM ImmunoTech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2006-04
- **Final completion:** 2006-04
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2013-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00215826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00215826, "Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00215826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*